Alessandro Di Federico: Honored to have our work highlighted in this months issue of Annals of Oncology

Alessandro Di Federico shared a post by Annals of Oncology on X, adding:

“Honored to have our work highlighted in this month’s issue of Annals of Oncology.

Many thanks to my mentor Mark Awad, to Jim Smithy, Stephanie Alden & all co-authors, and to patients involved in this study. Also special thanks to the editor-in-chief Tom Powles for selecting it!”

Quoting Annals of Oncology:

“Article of the Month: Dr Alessandro Di Federico introduces: Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer.”

Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer

Authors: A. Di Federico,  S.L. Alden, ∙ J.W. Smithy, B. Ricciuti, J.V. Alessi, X. Wang, F. Pecci, G. Lamberti, M.M. Gandhi,  V.R. Vaz, L.F. Spurr, L.M. Sholl, K.L. Pfaff, S.J. Rodig, Y.Y. Li, A.D. Cherniack, M. Nishino, B.E. Johnson and M.M. Awad.

Alessandro Di Federico is a Medical Oncologist, Ph.D. student, and research fellow in Oncology at the University of Bologna since 2023, conducts clinical and scientific activities in the field of thoracic oncology. His main research interests focus on identifying biomarkers capable of improving the personalization of therapies and, consequently, the survival of patients with lung cancer.

Dr. Federico engaged in national and international research projects, conducted lung cancer research at the Thoracic Oncology Department of the Dana-Farber Cancer Institute in Boston, affiliated with Harvard University, from July 2022 to November 2023; currently continued to collaborate with the Dana-Farber Cancer Institute remotely. He is author of more than 70 publications in peer-reviewed international journals, mainly in the field of thoracic oncology.